Status:
TERMINATED
Myocardial Perfusion Echocardiography to Detect Human Heart Transplant Rejection
Lead Sponsor:
Brigham and Women's Hospital
Collaborating Sponsors:
General Electric
Conditions:
Heart Transplantation
Eligibility:
All Genders
18-75 years
Brief Summary
The primary objective of this proposal is to show the efficacy of contrast enhanced ultrasonography in detecting heart transplant rejection in humans. The secondary objective is to demonstrate the eff...
Eligibility Criteria
Inclusion
- All adult subjects (ages 18 to 75) who have undergone heart transplant at Brigham and Women's Hospital
Exclusion
- hemodynamic instability (e.g., systolic blood pressure \< 90 mmHg)
- atrial fibrillation with rapid ventricular response (e.g., heart rate \> 120 bpm)
- premature atrial or ventricular complexes of a frequency that will not allow adequate echocardiographic assessment
- poor acoustic windows
- inability to provide informed consent
- any contraindication listed in the Optison package insert (i.e., history of an allergic reaction)
Key Trial Info
Start Date :
January 1 2015
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 1 2019
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT02300870
Start Date
January 1 2015
End Date
December 1 2019
Last Update
July 27 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02115